Laboratorios Farmaceuticos Rovi, S.A
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company also distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent thromboembolic disease; Enoxaparin biosimilar, a low-molecular-weight heparin; Neparvis for the treatment of symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for the treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and Medicebrán that are prescription medicines for treatment of attention deficit hyperactivity disorder in children and adolescents. The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT Exprès that are contrast injection systems and compatible disposable material. In addition, it provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves wholesalers, doctors, nursing staff, pharmacists, and patients. Laboratorios Farmaceuticos Rovi, S.A. was founded in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L. Show More...
-
Website http://www.rovi.es
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 84.70 EUR
-
Last Updated 25-04-2024
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share EUR 0.49 0.36 0.39 0.46 0.48 0.4 0.53 0.35 0.35 0.71 0.84 Dividends EUR 0.14 0.17 0.13 0.14 0.16 0.17 0.14 0.18 0.12 0.08 0.08 Payout Ratio % * 18.6 55.1 32.5 31.6 33.5 40.6 27.6 41.7 37.5 13.6 9.5 Shares Mil 50.0 50.0 50.0 50.0 50.0 50.0 49.0 49.0 51.0 55.0 55.0 Book Value Per Share * EUR 1.43 2.24 2.55 2.81 3.11 3.29 3.63 3.88 3.63 5.67 6.07 Free Cash Flow Per Share * EUR 0.13 0.1 0.12 0.12 -0.07 0.59 0.04 -0.26 -0.7 Return on Assets % 12.98 8.22 8.66 10.05 9.7 7.54 9.46 5.88 5.11 8.59 9.7 Financial Leverage (Average) 2.04 2.0 1.76 1.63 1.65 1.6 1.57 1.56 1.4 1.59 1.57 Return on Equity % 27.99 16.62 16.23 17.0 15.92 12.26 14.99 9.19 7.47 12.88 14.68 Return on Invested Capital % 20.24 12.08 12.73 14.19 13.92 10.58 12.5 8.03 6.62 10.93 12.42 Interest Coverage 17.51 8.97 10.56 17.31 12.14 12.73 31.47 18.3 24.42 65.63 56.72 Current Ratio 3.14 2.98 2.38 2.36 2.61 2.6 2.19 2.3 2.9 2.98 3.09 Quick Ratio 2.28 2.19 1.29 1.29 1.45 1.46 1.25 1.24 1.78 1.39 1.29 Debt/Equity 0.41 0.36 0.23 0.16 0.2 0.2 0.11 0.14 0.06 0.22 0.21